Keryx is finding it hard to hang on to the huge gains its shares made last week after investors responded enthusiastically to positive data from a Phase III study of the phosphorous-clearing drug Zerenex.
Following a well-defined trail of venture groups into late-stage investing, San Francisco-based Foresite Capital Management says it has wrapped a $100 million fund that will be heavily focused on the most disruptive and most promising late-stage technology it can find in biotech, genomics and diagnostics, among other healthcare fields.
Shares of Keryx Biopharmaceuticals roared into the fast lane this morning, shooting ahead 46% on the news that its long-awaited Phase III study of its phosphate binder Zerenex had wrapped with positive top-line data among kidney dialysis patients. The news positioned the small-cap biotech for marketing applications in the U.S. and Europe.
Canada's Aeterna Zentaris put out the word this morning that perifosine flamed out in a late-stage cancer study conducted by its partner Keryx Biopharmaceuticals.
Keryx Biopharmaceuticals' ( $KERX ) phosphate-lowering drug Zerenex proved effective in a late-stage study, positioning the biotech to make a 2012 run at the market-leading therapy by offering dialysis
Keryx Biopharmaceuticals says that its experimental late-stage cancer drug perifosine won its second orphan drug classification from the FDA, helping fuel a rally in its share price. Already dubbed
With a late-stage trial for the colorectal cancer drug KRX-0401 looming this quarter, Aeterna Zentaris and partner Keryx say they won fast-track status from the FDA for the program. Keryx shares
Shares of Keryx Pharmaceuticals jumped more than 12 percent after its experimental colon cancer drug hit a trio of key goals in a mid-stage clinical trial. Researchers say the drug, KRX-0401 or
Shares of Keryx Biopharmaceuticals zoomed up to a 52-week high this morning after the developer announced that the FDA had extended orphan drug status to its late-stage cancer drug KRX-0401. Keryx
Less than a month after seeing its lead drug candidate go down in flames in a late-stage trial, Keryx